November 4, 2019 10:44 AM EST

Sino Biopharm, OrbiMed back Merck-partnered Akesobio's bet on made-in-China antibodies

Amber Tong

In the latest boost for China’s flourishing antibody R&D scene, Merck-partnered Akesobio has bagged $150 million in Series D cash to push a slate of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sino Biopharm, OrbiMed back Merck-partnered Akesobio's bet on made-in-China antibodies

Amber Tong

Sign up to read this article for free.

A look at biotech's year of the megaround

Regeneron buys London-based ocular biotech

Neumora's major depression drug flunks first of three Phase 3 trials

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

Sino Bio­pharm, Or­biMed back Mer­ck-part­nered Ake­so­bio's bet on made-in-Chi­na an­ti­bod­ies

Amber Tong

Sign up to read this article for free.

more like this

A look at biotech's year of the megaround

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Neu­mora's ma­jor de­pres­sion drug flunks first of three Phase 3 tri­als

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

Pfiz­er ends work on Sang­amo's he­mo­phil­ia gene ther­a­py, crush­ing biotech's hopes

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

Sino Biopharm, OrbiMed back Merck-partnered Akesobio's bet on made-in-China antibodies

Regeneron buys London-based ocular biotech

Neumora's major depression drug flunks first of three Phase 3 trials

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

Pfizer ends work on Sangamo's hemophilia gene therapy, crushing biotech's hopes

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts